Literature DB >> 18780868

Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004.

Dianne Pulte1, Adam Gondos, Hermann Brenner.   

Abstract

BACKGROUND: Advances in the treatment of childhood hematologic malignancies have led to improvements in survival for several of these conditions during the past few decades, but most population-based survival data available to date refer only to patients diagnosed up to the mid-1990s.
METHODS: We used period analysis to assess trends in 5- and 10-year survival in US patients younger than 15 years of age at diagnosis with four hematologic malignancies--acute lymphoblastic leukemia, acute non-lymphoblastic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma--over three recent 5-year intervals, 1990-1994, 1995-1999, and 2000-2004, using data on a total of 6957 patients from the Surveillance, Epidemiology, and End Results database. Expected survival for 2005-2009 was estimated by modeling from trends in the preceding intervals.
RESULTS: Major improvements in 5- and 10-year relative survival between 1990-1994 and 2000-2004 were seen for acute lymphoblastic leukemia (from 80.2% to 87.5% and from 73.4% to 83.8%, respectively), acute non-lymphoblastic leukemia (from 41.9% to 59.9% and from 38.7% to 59.1%, respectively), and non-Hodgkin lymphoma (from 76.6% to 87.7% and from 73.0% to 86.9%, respectively). For those diagnosed with Hodgkin lymphoma, 5- and 10-year survival rates for the 1990-1994 period were 96.1% and 94.4%, respectively, and these rates did not change substantially in the later time periods. Projected 10-year survival rates for children diagnosed in the 2005-2009 period were 88.0% for acute lymphoblastic leukemia, 63.9% for acute non-lymphoblastic leukemia, 90.6% for non-Hodgkin lymphoma, and 94.3% for Hodgkin lymphoma.
CONCLUSIONS: Application of period analysis to a population-based study of childhood hematologic malignancies reveals ongoing increases in survival for three of the four common childhood hematologic malignancies.

Entities:  

Mesh:

Year:  2008        PMID: 18780868     DOI: 10.1093/jnci/djn276

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  41 in total

1.  Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia.

Authors:  Cassandra D Josephson; Suzanne Granger; Susan F Assmann; Marta-Inés Castillejo; Ronald G Strauss; Sherrill J Slichter; Marie E Steiner; Janna M Journeycake; Courtney D Thornburg; James Bussel; Eric F Grabowski; Ellis J Neufeld; William Savage; Steven R Sloan
Journal:  Blood       Date:  2012-04-26       Impact factor: 22.113

2.  Childhood and adolescent lymphoma in Spain: incidence and survival trends over 20 years.

Authors:  R Marcos-Gragera; M Solans; J Galceran; R Fernández-Delgado; A Fernández-Teijeiro; A Mateos; J R Quirós-Garcia; N Fuster-Camarena; V De Castro; M J Sánchez; P Franch; M D Chirlaque; E Ardanaz; C Martos; D Salmerón; R Peris-Bonet
Journal:  Clin Transl Oncol       Date:  2018-04-05       Impact factor: 3.405

3.  Survival disparities by insurance type for patients aged 15-64 years with non-Hodgkin lymphoma.

Authors:  Dianne Pulte; Lina Jansen; Hermann Brenner
Journal:  Oncologist       Date:  2015-04-15

4.  Implementation of a central line maintenance care bundle in hospitalized pediatric oncology patients.

Authors:  Michael L Rinke; Allen R Chen; David G Bundy; Elizabeth Colantuoni; Lisa Fratino; Kim M Drucis; Stephanie Y Panton; Michelle Kokoszka; Alicia P Budd; Aaron M Milstone; Marlene R Miller
Journal:  Pediatrics       Date:  2012-09-03       Impact factor: 7.124

Review 5.  Obesity in pediatric ALL survivors: a meta-analysis.

Authors:  Fang Fang Zhang; Michael J Kelly; Edward Saltzman; Aviva Must; Susan B Roberts; Susan K Parsons
Journal:  Pediatrics       Date:  2014-02-17       Impact factor: 7.124

6.  Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.

Authors:  Alan S Wayne; Robert J Kreitman; Harry W Findley; Glen Lew; Cynthia Delbrook; Seth M Steinberg; Maryalice Stetler-Stevenson; David J Fitzgerald; Ira Pastan
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

7.  Differential inequality trends over time in survival among U.S. children with acute lymphoblastic leukemia by race/ethnicity, age at diagnosis, and sex.

Authors:  Linwei Wang; Smita Bhatia; Scarlett Lin Gomez; Yutaka Yasui
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-09-16       Impact factor: 4.254

Review 8.  Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis.

Authors:  Michael G Brandel; Ali A Alattar; Brian R Hirshman; Xuezhi Dong; Kate T Carroll; Mir Amaan Ali; Bob S Carter; Clark C Chen
Journal:  J Neurooncol       Date:  2017-04-24       Impact factor: 4.130

9.  Population-based survival estimates for childhood cancer in Australia during the period 1997-2006.

Authors:  P D Baade; D R Youlden; P C Valery; T Hassall; L Ward; A C Green; J F Aitken
Journal:  Br J Cancer       Date:  2010-11-09       Impact factor: 7.640

10.  Amifostine reduces the seminiferous epithelium damage in doxorubicin-treated prepubertal rats without improving the fertility status.

Authors:  Vanessa Vendramini; Estela Sasso-Cerri; Sandra M Miraglia
Journal:  Reprod Biol Endocrinol       Date:  2010-01-10       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.